Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company harnessing human genetics to develop novel small molecule precision medicines for kidney and metabolic diseases. The company focuses on identifying and characterizing genetic variants associated with health and disease through its proprietary Compass platform, which enables variant functionalization to inform drug discovery and clinical development. Maze Therapeutics advances therapeutic candidates by mimicking protective genetic variants, correcting toxic variant effects, or targeting genetic modifiers to address unmet medical needs in specific patient populations. Its pipeline centers on small molecule inhibitors targeting diseases such as APOL1-mediated kidney disease and phenylketonuria, leveraging genetic insights to drive precision medicine approaches.

Maze Therapeutics generates revenue primarily through upfront payments, milestone payments, and royalties from licensing agreements with pharmaceutical and biotechnology partners for programs discovered using its Compass platform. The company has entered into exclusive licensing arrangements for targets outside its core focus areas, including Pompe disease with Shionogi, amyotrophic lateral sclerosis programs with Neurocrine Biosciences and Trace Neuroscience, and glaucoma-related research through its equity interest in Broadwing. These partnerships provide near-term financial support while allowing Maze Therapeutics to retain focus on advancing its wholly-owned clinical programs in kidney and metabolic diseases. Revenue is not currently generated from product sales, as all therapeutic candidates remain in clinical or preclinical development.

The company operates through the following segments: Kidney and Metabolic Diseases, and Partnered Programs.

• The Kidney and Metabolic Diseases segment encompasses the discovery, development, and clinical advancement of small molecule therapeutics targeting genetic drivers of kidney and metabolic disorders. This includes the APOL1 inhibitor MZE829 for APOL1-mediated kidney disease, which has demonstrated proof of concept in Phase 2 trials, and the SLC6A19 inhibitor MZE782 for phenylketonuria and chronic kidney disease, which completed Phase 1 trials and is preparing for Phase 2 studies. The segment also includes preclinical research programs exploring additional targets using the Compass platform to expand the pipeline in areas of significant unmet medical need.

• The Partnered Programs segment comprises therapeutic candidates identified through the Compass platform that have been licensed to third-party pharmaceutical and biotechnology companies for further development and commercialization. This includes MZE001 for Pompe disease, exclusively licensed to Shionogi, which received an upfront payment and is eligible for milestones and royalties. Additional partnered programs involve ATXN2 for amyotrophic lateral sclerosis licensed to Neurocrine Biosciences, UNC13A for amyotrophic lateral sclerosis and frontotemporal dementia licensed to Trace Neuroscience, and ANGPTL7 for glaucoma through the Broadwing joint venture with Alloy Therapeutics. These partnerships validate the Compass platform’s broad applicability across disease areas while generating non-dilutive revenue.

Maze Therapeutics holds a distinctive position in the biotechnology industry through its integration of human genetics and functional genomics via the Compass platform, enabling precise patient stratification and target validation in kidney and metabolic diseases. While it faces competition from larger pharmaceutical companies developing APOL1 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, and phenylalanine hydroxylase activators, its competitive advantage lies in its proprietary ability to identify and validate genetic modifiers and protective variants to inform mechanism-based drug design. The company’s focus on genetically defined subsets of prevalent diseases allows for differentiated approaches in crowded therapeutic areas, supported by early clinical signals of efficacy and tolerability in its lead programs.

Maze Therapeutics serves patients with genetically defined forms of kidney and metabolic diseases, including individuals with APOL1-mediated kidney disease, phenylketonuria, and chronic kidney disease. The company’s therapeutic candidates are designed for specific patient populations identified through genetic screening, such as those of West African ancestry with high-risk APOL1 variants or individuals with specific SLC6A19 genotypes. While the filing does not disclose specific customer names for its partnered programs, the company engages with pharmaceutical partners, contract manufacturing organizations, and clinical trial sites to support development and advance its pipeline toward potential commercialization.